Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.050 Biomarker group BEFREE Tumor-associated MUC1 binds to Siglec-9, which is expected to mediate tumor cell growth and negative immunomodulation. 24924635 2014
CUI: C0017636
Disease: Glioblastoma
Glioblastoma 		0.010 Biomarker disease BEFREE Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. 31489145 2019
CUI: C0278878
Disease: Adult Glioblastoma
Adult Glioblastoma 		0.010 Biomarker disease BEFREE Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. 31489145 2019
CUI: C0280474
Disease: Childhood Glioblastoma
Childhood Glioblastoma 		0.010 Biomarker disease BEFREE Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. 31489145 2019
CUI: C1621958
Disease: Glioblastoma Multiforme
Glioblastoma Multiforme 		0.010 Biomarker disease BEFREE Glioblastoma EVs showed significant binding to Siglec-9, which is highly expressed on DCs. 31489145 2019
CUI: C1519680
Disease: Tumor Immunity
Tumor Immunity 		0.010 Biomarker phenotype BEFREE Siglec 9 on neutrophils and Siglec 7 on NK cells are prominent examples of inhibitory Siglecs that can potentially dampen anti-tumor immunity. 28258691 2017
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis 		0.010 AlteredExpression disease BEFREE Changes in Siglec-9 sialoglycan ligand expression on vascular endothelial cells may be a natural response to the initial steps of atherosclerosis and might be a potential target to regulate inflammation in diabetic angiopathy. 30471282 2019
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis 		0.010 AlteredExpression disease BEFREE Changes in Siglec-9 sialoglycan ligand expression on vascular endothelial cells may be a natural response to the initial steps of atherosclerosis and might be a potential target to regulate inflammation in diabetic angiopathy. 30471282 2019
CUI: C0008055
Disease: Chikungunya Fever
Chikungunya Fever 		0.010 AlteredExpression disease BEFREE Expression of Siglec-9 on monocytes; which can modulate oxidative stress is studied along with intracellular reactive oxygen species (ROS), cellular lipid and protein damage markers in chikungunya patients with/without persisting polyarthralgia along with healthy controls. 29898618 2018
CUI: C0162296
Disease: Polyarthralgia
Polyarthralgia 		0.010 AlteredExpression disease BEFREE Expression of Siglec-9 on monocytes; which can modulate oxidative stress is studied along with intracellular reactive oxygen species (ROS), cellular lipid and protein damage markers in chikungunya patients with/without persisting polyarthralgia along with healthy controls. 29898618 2018
CUI: C0003864
Disease: Arthritis
Arthritis 		0.010 Biomarker disease BEFREE Furthermore, administration of recombinant human Siglec-9 Fc chimera protein significantly attenuated collagen-induced arthritis development in vivo and in vitro by reciprocal regulation of the differentiation of Th17 and Treg cells. 28273363 2017
CUI: C2985280
Disease: Blood Protein Measurement
Blood Protein Measurement 		0.100 GeneticVariation phenotype GWASCAT Genomic atlas of the human plasma proteome. 29875488 2018
CUI: C0024115
Disease: Lung diseases
Lung diseases 		0.010 Biomarker group BEFREE Given that neutrophils are probably a major culprit in the generation and perpetuation of inflammation, targeting Siglec-9 could be beneficial for the treatment of severe asthma, chronic obstructive pulmonary disease, and related pulmonary disorders characteristic of neutrophilia. 29306942 2018
CUI: C3665444
Disease: Neutrophilia (disorder)
Neutrophilia (disorder) 		0.010 Biomarker disease BEFREE Given that neutrophils are probably a major culprit in the generation and perpetuation of inflammation, targeting Siglec-9 could be beneficial for the treatment of severe asthma, chronic obstructive pulmonary disease, and related pulmonary disorders characteristic of neutrophilia. 29306942 2018
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.050 Biomarker group BEFREE Here we found that this cancer-specific MUC1 glycoform, through engagement of Siglec-9, 'educated' myeloid cells to release factors associated with determination of the tumor microenvironment and disease progression. 27595232 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.050 Biomarker group BEFREE Here we used affinity chromatography of tumor cell extracts to identify LGALS3BP as a novel sialic acid-dependent ligand for human Siglec-9 and for other immunomodulatory Siglecs, such as Siglec-5 and Siglec-10. 25320078 2014
CUI: C0524909
Disease: Hepatitis B, Chronic
Hepatitis B, Chronic 		0.010 Biomarker disease BEFREE Here, we studied the potential regulatory roles of NK Siglec-9 in the pathogenesis of chronic hepatitis B (CHB) infection. 29899741 2018
CUI: C0025202
Disease: melanoma
melanoma 		0.010 AlteredExpression disease BEFREE However, here, we report that the majority of intratumoral, but not peripheral blood, cytotoxic CD8<sup>+</sup> T cells expressed Siglec-9 in melanoma. 30988027 2019
CUI: C0003873
Disease: Rheumatoid Arthritis
Rheumatoid Arthritis 		0.010 Biomarker disease BEFREE In conclusion, Siglec-9 may serve as a potential diagnostic and therapeutic target for RA. 28273363 2017
CUI: C0024117
Disease: Chronic Obstructive Airway Disease
Chronic Obstructive Airway Disease 		0.020 Biomarker disease BEFREE In conclusion, Siglec-9 was complementarily increased to induce a negative feedback loop to limit neutrophil activation in COPD, sSiglce-9 enhanced neutrophil ROS and chemotaxis toward IL-8 likely via competitively inhibiting ligands binding to Siglec-9. 28860481 2017
CUI: C0007097
Disease: Carcinoma
Carcinoma 		0.010 Biomarker group BEFREE In keeping with this, a human polymorphism that reduced Siglec-9 binding to carcinomas was associated with improved early survival in non-small-cell lung cancer patients, which suggests that Siglec-9 might be therapeutically targeted within the right time frame and stage of disease. 25225409 2014
CUI: C0024117
Disease: Chronic Obstructive Airway Disease
Chronic Obstructive Airway Disease 		0.020 GeneticVariation disease BEFREE Influence of SIGLEC9 polymorphisms on COPD phenotypes including exacerbation frequency. 27878892 2017
CUI: C0151517
Disease: Complete atrioventricular block
Complete atrioventricular block 		0.010 Biomarker disease BEFREE Neutralization of Siglec-9 restored cytokine synthesis and degranulation of NK cells from CHB patients. 29899741 2018
CUI: C0036690
Disease: Septicemia
Septicemia 		0.010 Biomarker disease BEFREE Our findings have implications for the inhibitory role of siglec-9 on human neutrophils in sepsis and acute lung injury. 24895121 2014
CUI: C0243026
Disease: Sepsis
Sepsis 		0.010 Biomarker disease BEFREE Our findings have implications for the inhibitory role of siglec-9 on human neutrophils in sepsis and acute lung injury. 24895121 2014